
|Videos|November 4, 2021
Controlling ACE and ARB Dosing Can Benefit Treatment of Chronic Kidney Disease
Chi Chu, MD, an assistant professor in the division of nephrology at the University of California San Francisco, discusses how ACE and ARB therapies can be applied to chronic kidney disease, and the benefits of controlling the dosage.
Advertisement
In a Pharmacy Times® interview, Chi Chu, MD, an assistant professor in the division of nephrology at the University of California San Francisco, spoke about his 2021 ASN Kidney Week presentation on the submaximal dose of angiotensin converting enzyme (ACE) inhibitor and angiotensin II receptor blockers (ARB) for individuals with proteinuria.
He discussed how ACE and ARB therapies can be applied to chronic kidney disease, and the benefits of controlling the dosage.
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
CVS Health Expands GLP-1 Access With $29 Visits, Lilly Deal
2
FDA Approves mFlusiva, the First mRNA-Based Influenza Vaccine
3
The Side Door We Could Close: A Pharmacy Perspective on Menopause, Access, and the Leadership Pipeline
4
Study Reveals a Widening Gap Between Buprenorphine Prescribing and Dispensing
5



































































































